KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) EBITDA (2016 - 2026)

Neogenomics filings provide 17 years of EBITDA readings, the most recent being -$18.2 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 34.44% to -$18.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$106.3 million, a 18.95% decrease, with the full-year FY2025 number at -$115.9 million, down 25.81% from a year prior.
  • EBITDA hit -$18.2 million in Q1 2026 for Neogenomics, down from -$13.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$13.4 million in Q4 2025 to a low of -$52.0 million in Q1 2022.
  • Median EBITDA over the past 5 years was -$27.0 million (2025), compared with a mean of -$28.9 million.
  • Biggest five-year swings in EBITDA: tumbled 244.4% in 2022 and later surged 38.76% in 2023.
  • Neogenomics' EBITDA stood at -$26.4 million in 2022, then rose by 29.6% to -$18.6 million in 2023, then rose by 0.93% to -$18.4 million in 2024, then rose by 27.1% to -$13.4 million in 2025, then plummeted by 35.98% to -$18.2 million in 2026.
  • The last three reported values for EBITDA were -$18.2 million (Q1 2026), -$13.4 million (Q4 2025), and -$27.0 million (Q3 2025) per Business Quant data.